ArticlePharmaceutics2019
Utilizing Liposomal Quercetin and Gallic Acid in Localized Treatment of Vaginal
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.International journal of molecular sciences · 2024Pooled it
- Stepwise effects of formulation additives and process parameters on ethanol injection-prepared nanoliposomes for cancer delivery: a preformulation study.Scientific reports · 2026Article
- Physicochemical Stability and Bio-Functionality of Liposome-Encapsulated Macadamia Husk Phenolic Extract.Foods (Basel, Switzerland) · 2026Article
- Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy.Current pharmaceutical design · 2026Review
- Harnessing liposomal delivery to boost polyphenols' potential in chronic wound therapy.Frontiers in drug delivery · 2026Article
- Anacardiaceae Family: Effect of Isolated Compounds and Other Identified Phytochemicals Against Clinically RelevantAntibiotics (Basel, Switzerland) · 2025Review
- A Comprehensive Review on Polyphenols based Nanovesicular System for Topical Delivery.Current drug delivery · 2025Review
- From plants to particles: herbal solutions and nanotechnology combating resistant vulvovaginal candidiasis.Therapeutic delivery · 2024Review
- In Situ Forming Bioartificial Hydrogels with ROS Scavenging Capability Induced by Gallic Acid Release with Potential in Chronic Skin Wound Treatment.Gels (Basel, Switzerland) · 2023Article
- Formation of a traditional Chinese medicine self-assembly nanostrategy and its application in cancer: a promising treatment.Chinese medicine · 2023Review
- Lecithin and Chitosan as Building Blocks in Anti-Pharmaceuticals (Basel, Switzerland) · 2023Article
- Quercetin-loaded Liposomes Effectively Induced Apoptosis and Decreased the Epidermal Growth Factor Receptor Expression in Colorectal Cancer Cells: AnIranian journal of medical sciences · 2023Article
- Organically surface engineered mesoporous silica nanoparticles control the release of quercetin by pH stimuli.Scientific reports · 2022Article
- Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginalPharmaceutics · 2022Article
- Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2021Review
- Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating miR-223-3p/FOXO3.Cell cycle (Georgetown, Tex.) · 2021Article
- Article
- Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection.Pharmaceutics · 2020Article
- Phytochemical Composition and In Vitro Antimicrobial Activity of Essential Oils from theAntibiotics (Basel, Switzerland) · 2020Article
- Following the Fate of Dye-Containing Liposomes In Vitro.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is a widely spread fungal infection that causes itching, pain and inflammation at the vaginal site. Although common, currently available treatment suffers from limited efficacy and high recurrence. In addition, the growing problem of resistance to azole drugs used in current treatments emphasizes the need for superior treatment options. Antimicrobial polyphenols are an attractive approach offering multitargeting therapy. We aimed to develop novel liposomes for simultaneous delivery of two polyphenols (quercetin, Q, and gallic acid, GA) that, when released within the vaginal cavity, act in synergy to eradicate infection while alleviating the symptoms of VVC. Q was selected for its anti-itching and anti-inflammatory properties, while GA for its reported activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.